Hearing loss due to aging, noise and certain cancer therapy drugs and antibiotics has been irreversible because scientists have not been able to reprogram existing cells to develop… read more.
A new protein-based antiviral nasal spray developed by researchers at Northwestern University, University of Washington and Washington University at St. Louis is being advanced toward Phase I human… read more.
Bristol Myers Squibb announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of Opdivo (nivolumab) plus Yervoy… read more.
Preclinical models that recapitulate aspects of human airway disease are essential for the advancement of novel therapeutics and vaccines. In the current study published in the journal mBIO, researchers… read more.
A new study has found no link between a strep throat infection and the development of tics in children who have a parent or sibling with a chronic… read more.
Nucala (mepolizumab) is now approved in Canada as an add-on maintenance treatment with intranasal corticosteroids in adult patients with severe chronic rhinosinusitis with nasal polyps (CRSwNP) inadequately controlled… read more.
Oyster Point Pharma, Inc. announced that the FDA has approved Tyrvaya (varenicline solution) Nasal Spray 0.03 mg for the treatment of the signs and symptoms of dry eye… read more.
Impel NeuroPharma, Inc. announced that the FDA approved Trudhesa (dihydroergotamine mesylate) nasal spray (0.725 mg per spray) for the acute treatment of migraine with or without aura in… read more.
Merck Inc., announced the FDA has approved Vaxneuvance (Pneumococcal 15-valent Conjugate Vaccine) (pronounced VAKS-noo-vans) for active immunization for the prevention of invasive disease caused by Streptococcus pneumoniae serotypes… read more.
Journal of Clinical Investigation The discovery that multiciliated cells in the nasal epithelium are the first cells to be targeted in early COVID-19 infection might provide the rationale… read more.
Edwards Lifesciences announced the results of a real-world study comparing outcomes for patients with bicuspid aortic stenosis (AS) who were treated with SAPIEN 3 and SAPIEN 3 Ultra… read more.